Drug or treatment

Tucatinib clinical trials

• 12Clinical trials
• 33Countries

Newest trials

All recruiting trials (12)

• Tucatinib with trastuzumab and capecitabine for HER2‑positive metastatic breast cancer in routine care

  This project will see if tucatinib combined with trastuzumab and capecitabine works and is safe for people with HER2‑positive metastatic breast cancer who have had at least two prior anti‑HER2 treatments.

  Recruiting at 13 sites Fondazione Oncotech · Avellino, AV and 29 other locations · NCT07583485

• RO7771950 versus tucatinib with trastuzumab and capecitabine for HER2-positive locally advanced or metastatic breast cancer

  This test will see if RO7771950 combined with trastuzumab and capecitabine works better than tucatinib combined with the same drugs for people with HER2-positive locally advanced or metastatic breast cancer.

  Recruiting at 219 sites Phase 2/3 Hoffmann-La Roche · Huntsville, Alabama and 218 other locations · NCT07413939

• Tucatinib plus trastuzumab for HER3-mutant, HER2-not amplified metastatic breast cancer

  This trial will test whether combining tucatinib and trastuzumab helps people with metastatic or unresectable breast cancer whose tumors are HER2-negative but carry activating ERBB3 (HER3) mutations.

  Recruiting Phase 2 Institut Curie · Bordeaux and 8 other locations · NCT07193394

• Nurse-led patient navigation for HER2+ metastatic breast cancer patients on tucatinib, trastuzumab, and capecitabine

  This study tests a nurse-delivered patient navigation program to help women with HER2+ metastatic breast cancer who are taking tucatinib, trastuzumab, and capecitabine see if the program is doable and acceptable.

  Recruiting Duke University · Durham, North Carolina · NCT06983691

• Neoadjuvant treatment for HER2-positive breast cancer without chemotherapy

  This study is testing a new treatment using tucatinib, trastuzumab, and pertuzumab for people with stage II-III HER2-positive breast cancer to see if they can be treated without chemotherapy.

  Recruiting Phase 1 The Netherlands Cancer Institute · Amsterdam · NCT06162559

• Tucatinib combined with radiation for HER2-positive breast cancer with leptomeningeal disease

  This study is testing if combining radiation with a new treatment for HER2-positive breast cancer can help patients with brain involvement live longer and feel better.

  Recruiting at 2 sites Phase 2 Sunnybrook Health Sciences Centre · Ottawa, Ontario and 1 other locations · NCT06016387

• Combination treatment for metastatic HER2-positive breast cancer

  This study is testing a new combination of medications for people with HER2-positive metastatic breast cancer who haven't responded to previous treatments, to see if it can help them feel better and manage their disease.

  Recruiting at 9 sites Phase 2 Institut Curie · Clermont-Ferrand, Clermont Ferrand and 12 other locations · NCT05955170

• Treatment for breast cancer patients with leptomeningeal disease

  This study is testing a new treatment combining tucatinib, capecitabine, and intrathecal trastuzumab to see if it can help people with HER2-positive metastatic breast cancer and leptomeningeal disease live longer.

  Recruiting at 10 sites Phase 2 Unicancer · Bordeaux and 10 other locations · NCT05800275

• Combining tucatinib and Doxil for HER2 positive metastatic breast cancer

  This study is testing if combining tucatinib with Doxil can help people with HER2 positive metastatic breast cancer who have already tried other treatments.

  Recruiting at 7 sites Phase 2 SCRI Development Innovations, LLC · Columbia, Maryland and 7 other locations · NCT05748834

• Combination treatment for HER2-positive metastatic solid tumors with brain metastases

  This study is testing if a combination of two drugs can help people with HER2-positive metastatic solid tumors that have spread to the brain feel better and live longer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05673928

• Combining Tucatinib and Trastuzumab for HER2 Positive Rectal Cancer

  This study is testing if combining two cancer drugs, tucatinib and trastuzumab, with standard chemotherapy can help people with HER2 positive rectal cancer have better treatment results.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT05672524

• Combination treatment for HER2 positive metastatic colorectal cancer

  This study is testing a new combination of tucatinib, trastuzumab, and mFOLFOX6 to see if it helps people with HER2 positive metastatic colorectal cancer more than the usual treatments.

  Recruiting at 298 sites Phase 3 Seagen Inc. · Glendale, Arizona and 365 other locations · NCT05253651

Quick answers

How many clinical trials of Tucatinib are recruiting right now?

12, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 33 countries. The most sites are in United States (6 trials), France (5 trials), Italy (3 trials), Canada (3 trials), Netherlands (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 7, Phase 1: 1, Phase 2/3: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →